DSM expands gut health ingredients portfolio with acquisition of BioCare Copenhagen

636504816380196279probioticbottle.jpg

02 Jan 2018 --- Royal DSM has acquired BioCare Copenhagen A/S to expand its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7 percent per year. Financial details will not be disclosed at this time.

BioCare Copenhagen, a privately-held company founded in 2012, focuses on probiotics and is specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections and immunity. The company’s activities are based on research conducted at the Danish hospitals. BioCare Copenhagen was established as a joint venture between Borean Innovation, the Danish Ministry of Science, Technology and Innovation and the management team Søren B. Thomsen (CEO) and Jesper Gantzel (COO).

BioCare Copenhagen offers white label probiotic supplements and complete product concepts with strong consumer appeal. The company has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.

DSM already has a strong position in gut health solutions with its Culturelle product range as well as with its ingredient brands Oatwell and Tolerase. The company sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health. Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health. 

DSM’s ambition in addressing the gut microbiome and its portfolio of nutritional ingredients are very synergetic with BioCare Copenhagen’s approach and products, and the combination is well-catered to address the existing and emerging gut health areas, DSM reports.

RELATED ARTICLES
Homepicture

DSM benefits from high vitamin prices in Q1, raises outlook

12 Apr 2018 DSM has pre-announced better-than-expected ...

Homepicture

Clinical merger: Novartis acquires AveXis for US$8.7bn, expands in gene therapy

09 Apr 2018 Novartis has entered into an agreement and plan ...

Homepicture

GSK to take full ownership of Novartis stake in Consumer Healthcare Business for US$13bn

27 Mar 2018 GlaxoSmithKline (GSK) has reached an agreement ...

Homepicture

Probi signs agreement with pharma company Cilag on probiotic OTC product

23 Mar 2018 Probi has signed a long-term agreement with ...